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Aims The relationship between serum potassium concentration and outcomes in patients with heart failure and preserved
ejection fraction (HFpEF) is not well-established. The aim of this study was to explore the association between serum
potassium and clinical outcomes in the PARAGON-HF trial in which 4822 patients with HFpEF were randomised to
treatment with sacubitril/valsartan or valsartan.
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Methods
and results
The relationship between serum potassium concentrations and the primary study composite outcome of total (first
and recurrent) heart failure hospitalisations and cardiovascular death was analysed. Hypo-, normo-, and hyperkalaemia
were defined as serum potassium <4 mmol/L, 4–5 mmol/L and >5 mmol/L, respectively. Both screening and
time-updated potassium (categorical and continuous spline-transformed) were studied. Patient mean age was 73 years
and 52% were women. Patients with higher baseline potassium more often had an ischaemic aetiology and diabetes
and mineralocorticoid receptor antagonist treatment. Compared with normokalaemia, both time-updated (but not
screening) hypo- and hyperkalaemia were associated with a higher risk of the primary outcome [adjusted hazard
ratio (HR) for hypokalaemia 1.55, 95% confidence interval (CI) 1.30–1.85; P < 0.001, and for hyperkalaemia HR
1.21, 95% CI 1.02–1.44; P = 0.025]. Hypokalaemia had a stronger association with a higher risk of all-cause,
cardiovascular and non-cardiovascular death than hyperkalaemia. The association of hypokalaemia with increased
risk of all-cause and cardiovascular death was most marked in participants with impaired kidney function (interaction
P< 0.05). Serum potassium did not significantly differ between sacubitril/valsartan and valsartan throughout the
follow-up.
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Conclusions Both hypo- and hyperkalaemia were associated with heart failure hospitalisation but only hypokalaemia was
associated with mortality, especially in the context of renal impairment. Hypokalaemia was as strongly associ-
ated with death from non-cardiovascular causes as with cardiovascular death. Collectively, these findings sug-
gest that potassium disturbances are a more of a marker of HFpEF severity rather than a direct cause of
death.
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Introduction
Both hypo- and hyperkalaemia are common in heart failure with
preserved ejection fraction (HFpEF). Both incident hypokalaemia
and hyperkalaemia are associated with a worse prognosis with
a U-shaped association between potassium and mortality.1–4
Patients with HFpEF are often elderly with concomitant chronic
kidney disease (CKD), which may increase the risk for abnor-
malities in potassium homeostasis during treatment.5 Moreover,
some commonly used medications [e.g. loop and thiazide-type
diuretics, mineralocorticoid receptors antagonists (MRAs),
angiotensin-converting enzyme inhibitors (ACEi)/angiotensin
receptor blockers (ARBs), and beta-blockers] may contribute to
dyskalaemia.6
Both severe hypo- and hyperkalaemia may increase the risk
of arrhythmias and sudden cardiac death, especially if these per-
turbations develop rapidly and are marked (e.g. serum potas-
sium <2 mmol/L or >7 mmol/L).7–9 The reason why less extreme
potassium abnormalities are associated with poor outcomes is
uncertain, and these may just be a marker of HFpEF sever-
ity (or associated comorbidities), rather than a direct cause of
death. In patients with heart failure and reduced ejection frac-
tion (HFrEF) the association between higher potassium concen-
trations and worse outcomes has been blamed on the withdrawal
of renin–angiotensin–aldosterone system (RAAS) blockers but
such a mechanism is less plausible in HFpEF where the bene-
fit of RAAS blockers is uncertain.10–14 Conversely, in both heart
failure phenotypes, hypokalaemia may reflect intensity of diure-
sis, in turn representing severity of heart failure.5,15–18 Compared
to HFrEF, fewer studies have examined the relationship between
serum potassium and outcomes in HFpEF. Moreover, the inci-
dence of both hypo- and hyperkalaemia with sacubitril/valsartan
vs. valsartan has not been documented yet. Therefore, we stud-
ied the efficacy and safety of sacubitril/valsartan, compared to
valsartan, in 4822 patients with HFpEF in PARAGON-HF (Effi-
cacy and Safety of LCZ696 Compared to Valsartan, on Morbidity
and Mortality in Heart Failure Patients With Preserved Ejection
Fraction).19
We examined the relationships between serum potassium con-
centration (both categorical and continuous) and outcomes in
patients with HFpEF enrolled in PARAGON-HF and the poten-
tial interaction with renal function. We also studied the effect of
trial treatment on the incidence of hyperkalaemia and hypokalaemia



































































Study design and population
The design and primary results of PARAGON-HF are published.19,20
Briefly, patients aged ≥50 years were eligible if they had New York
Heart Association functional class II–IV symptoms, preserved left
ventricular ejection fraction (LVEF ≥45%), additional evidence of
structural heart disease (left ventricular hypertrophy, left atrial
enlargement, or both), need for diuretic therapy and elevated
levels of natriuretic peptides. Key exclusion criteria included any
prior LVEF <40%, acute decompensated heart failure at the time
of screening, symptomatic hypotension (or systolic blood pres-
sure <100 mmHg at screening), estimated glomerular filtration rate
(eGFR) <30 mL/min/1.73 m2, or serum potassium >5.2 mmol/L at
screening.
Patients undertook sequential valsartan and sacubitril/valsartan
run-in periods before randomisation. During the 1- to 2-week val-
sartan run-in, valsartan 40 mg or 80 mg was administered twice daily;
patients receiving the lower dose initially were increased to 80 mg
twice daily. Patients tolerating valsartan were then exposed to a fur-
ther 2- to 4-week run-in period during which they received sacubi-
tril/valsartan 49/51 mg twice daily. Only patients who tolerated both
study drugs were eligible for randomisation. At randomisation, doses
were increased to sacubitril/valsartan 97/103 mg twice daily or valsar-
tan 160 mg twice daily when possible.
The ethics committee at each participating site approved the
study protocol, and participants provided written informed con-




Serum potassium and creatinine levels were measured at screening,
during the run-in period, at randomisation, 1 and 4 months following
randomisation, and in 4-month intervals thereafter at each study site.
eGFR was calculated using the Modification of Diet in Renal Disease
formula.21
By protocol, a patient with a serum potassium >5.3 mmol/L at any
time after randomisation required confirmation in a non-haemolysed
sample and further checks of potassium concentration until the potas-
sium was stable and not rising into the range of concern (≥5.5 and
<6.0 mmol/L) or potential danger (≥6.0 mmol/L). Guidance was given
on modification of trial treatment (including dose reduction or dis-
continuation), concomitant therapy and diet, to correct elevation in
potassium. Hypokalaemia was managed at the discretion of the treating
physician.19
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Endpoints
In the present analysis we studied the associations of serum potassium
(categorical and continuous, using both the screening and time-updated
values) with: (i) the trial primary endpoint, a composite of total (first
and recurrent) heart failure hospitalisations and cardiovascular death;
(ii) total heart failure hospitalisations; (iii) cardiovascular death; (iv)
non-cardiovascular death; and (v) all-cause death. There were too few
sudden cardiac deaths and ‘pump failure’ deaths for meaningful analysis.
Statistical analysis
Continuous variables are expressed as mean± standard deviation
or median (percentile25–75). Categorical variables are presented
as absolute numbers and percentages. The baseline characteristics
were compared between the following potassium categories of
<4 (hypokalaemia), 4–5 (normokalaemia), and >5 mmol/L (hyper-
kalaemia) at screening, using ANOVA or Kruskal–Wallis tests as
appropriate. The variables with strongest association with hypo-
and hyperkalaemia during the follow-up were assessed using a step-
wise forward multinomial logistic model with normokalaemia set as
reference category and all the variables with a P-value <0.1 from
Table 1 included in the model as independent variables. Several models
were used to study the association of serum potassium with the
outcomes. The associations between serum potassium at screening
and the outcomes of interest were studied using Cox models with
serum potassium as both a categorical and a continuous variable
(using restricted cubic splines22). Repeated potassium measurements
throughout the follow-up period were incorporated in time-updated
models (that take into account the last available potassium value
before each event), also examining potassium as a categorical and a
continuous variable (spline transformed). For the composite of total
(first and recurrent) heart failure hospitalisations and cardiovascular
death, as well as total heart failure hospitalisations, a semiparametric
proportional rates method (LWYY) and a joint gamma frailty model
stratified according to geographic region was used, in concordance
with the primary report of the trial.19 The regression estimates
are presented as hazard ratios (HR) with 95% confidence intervals
(CIs). The adjusted models were corrected for age, sex, race, region,
systolic blood pressure, heart rate, body mass index, eGFR (cate-
gorical: <60 vs. ≥60 mL/min/1.73 m2), blood urea nitrogen, ischaemic
cardiomyopathy, LVEF, N-terminal pro-B-type natriuretic peptide,
New York Heart Association (NYHA) class, hypertension, diabetes,
atrial fibrillation, prior heart failure hospitalisation, prior stroke,
use of diuretics (non-MRAs), beta-blockers, MRAs, and treatment
group allocation (sacubitril/valsartan or valsartan) at randomisation.
In the time-updated models, we pre-specified two interaction terms,
one with potassium by eGFR (fitted as a time-updated covariate)
and another with potassium by treatment (sacubitril/valsartan vs.
valsartan) to assess whether the prognostic associations of serum
potassium could change by eGFR or by treatment, respectively. The
rationale for testing the interaction by renal function and treatment
allocation was based on the important impact of renal function on
both the prognostic and potassium levels in heart failure23 and testing
sacubitril/valsartan vs. valsartan in HFpEF was the main aim of the
PARAGON-HF trial. Whenever a statistically significant interaction
was found, the models were presented separately in the respective
subgroups. An exploratory landmark analysis studying the associations
between the number of hypo- and hyperkalaemia episodes (0, 1 and 2
or more) plus the average potassium levels during the first 8 months of



















































































.. power for this analysis) was also performed. Mixed-effects models
were used to analyse changes in serum potassium concentration over
time, according to randomised treatment group and whether patients
were treated with a MRA or not; a treatment-by-visit time interaction
term was forced in the model as fixed effect and the random effects
were set at the patient level. All statistical analyses were conducted in
Stata® version 16 (StataCorp LP, College Station, TX, USA). A P-value
<0.05 was accepted as the threshold for statistical significance without
correction for multiplicity of tests given the exploratory nature of this
analysis.
Results
Baseline characteristics and variables
associated with hypo- and hyperkalaemia
Baseline characteristics of patients in PARAGON-HF, accord-
ing to serum potassium levels at screening (<4 vs. 4–5 vs.
>5 mmol/L), are shown in Table 1. The were no significant differ-
ences with regard to age, sex, NYHA class, or ejection fraction
by potassium category. Patients with potassium <4 mmol/L were
more often from Asia-Pacific, North and Latin America, whereas
those with potassium >5 mmol/L were more often from Central
Europe. Patients with heart failure of ischaemic aetiology, diabetes
and those treated with an MRA had higher potassium levels at
screening.
Throughout the follow-up a blood urea nitrogen >8 mmol/L,
Central Europe region, White race, and diabetes were associ-
ated with incident hyperkalaemia at multiple visits, whereas high
blood pressure/hypertension history and the use of diuretics were
associated with incident hypokalaemia. Randomised assignment to
sacubitril/valsartan was not associated with either hypo- or hyper-
kalaemia throughout the follow-up. Non-randomised use of MRAs
was associated with incident hyperkalaemia at week 4 and week 32
only (online supplementary Table S1).
Post-hoc tests for the results displayed in Table 1 are presented
in online supplementary Table S2.
Clinical outcomes
Event rates related to screening potassium category, and
time-updated potassium, are presented in Table 2. Patients in
the lowest and highest time-updated potassium categories had a
higher risk of the primary outcome than those with a potassium
between 4 and 5 mmol/L. With normokalaemia (4–5 mmol/L)
used as the reference category, the adjusted time-updated
HR (95% CI) for the primary outcome in patients with inci-
dent hypokalaemia (potassium <4 mmol/L) was 1.55 (1.30–1.85)
(P < 0.001) and for patients with incident hyperkalaemia (potassium
>5 mmol/L) the adjusted time-updated HR was 1.21 (1.02–1.44)
(P = 0.025). The relationship between serum potassium as a
continuous (spline transformed) variable and the primary out-
come, suggests that potassium levels above 5.0 mmol/L and below
4.5 mmol/L are each associated with a higher risk of the primary
outcome (Figure 1). Similar findings were observed for total
heart failure hospitalisations alone. Incident hypokalaemia had
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Characteristics of the population by potassium categories at screening in the PARAGON-HF trial
Characteristics K+ <4 (n = 592) K+ 4–5 (n = 3877) K+ >5 (n = 327) P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 73± 9 73± 8 73± 8 0.68
Male sex 260 (43.9%) 1895 (48.9%) 162 (49.5%) 0.07
Race 0.001
White 444 (75.0%) 3170 (81.8%) 293 (89.6%)
Asian 96 (16.2%) 485 (12.5%) 26 (8.0%)
Black 29 (4.9%) 71 (1.8%) 2 (0.6%)
Other 23 (3.9%) 151 (3.9%) 6 (1.8%)
Region 0.001
North America 114 (19.3%) 419 (10.8%) 26 (8.0%)
Latin America 59 (10.0%) 294 (7.6%) 17 (5.2%)
Western Europe 178 (30.1%) 1113 (28.7%) 99 (30.3%)
Central Europe 128 (21.6%) 1441 (37.2%) 146 (44.6%)
Asia-Pacific or other 113 (19.1%) 610 (15.7%) 39 (11.9%)
SBP, mmHg 132±16 130±15 130±15 0.09
Heart rate, bpm 70±13 70±12 71±12 0.98
BMI, kg/m2 30.2± 5.4 30.2± 5.0 30.2± 4.8 0.98
eGFR, mL/min/1.73 m2 63.5±19.3 62.6±19.0 60.4±19.5 0.05
eGFR <60 mL/min/1.73 m2 279 (47.1%) 1886 (48.6%) 176 (53.8%) 0.14
BUN, mmol/L 7.74± 3.37 8.10± 3.17 8.79± 3.72 0.001
Ischaemic HF 176 (29.7%) 1417 (36.5%) 130 (39.8%) 0.002
LVEF, % 58.0± 7.7 57.5± 7.9 57.3± 8.3 0.22
NYHA class 0.79
I 18 (3.0%) 106 (2.7%) 13 (4.0%)
II 452 (76.4%) 3011 (77.7%) 245 (74.9%)
III 119 (20.1%) 746 (19.2%) 67 (20.5%)
IV 3 (0.5%) 14 (0.4%) 2 (0.6%)
Hypertension 569 (96.1%) 3705 (95.6%) 310 (94.8%) 0.65
Diabetes 246 (41.6%) 1645 (42.4%) 171 (52.3%) 0.002
Atrial fibrillation 210 (35.5%) 1243 (32.1%) 99 (30.3%) 0.18
Prior HF hospitalisation 286 (48.3%) 1849 (47.7%) 171 (52.3%) 0.28
MI 124 (20.9%) 884 (22.8%) 75 (22.9%) 0.6
Stroke 77 (13.0%) 399 (10.3%) 32 (9.8%) 0.12
Prior ACEi 217 (36.7%) 1632 (42.1%) 132 (40.4%) 0.041
Prior ARB 282 (47.6%) 1799 (46.4%) 168 (51.4%) 0.21
Diuretic 565 (95.4%) 3703 (95.5%) 317 (96.9%) 0.47
Beta-blocker 470 (79.4%) 3090 (79.7%) 261 (79.8%) 0.98
MRA 130 (22.0%) 1004 (25.9%) 105 (32.1%) 0.003
NT-proBNP, pg/mL 979 [484–1847] 901 [465–1562] 885 [441–1747] 0.06
Sacubitril/valsartan 274 (46.3%) 1968 (50.8%) 165 (50.5%) 0.13
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate;
HF, heart failure; K+ , serum potassium (mmol/L); LVEF, left ventricular ejection fraction; MI, myocardial infraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP,
N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure.
a stronger association with cardiovascular death than incident
hyperkalaemia. Similarly, hypokalaemia had a stronger association
with non-cardiovascular death [adjusted time-updated HR (95%
CI) 1.72 (1.20–2.48); P = 0.003 and 0.93 (0.61–1.40); P = 0.71, for
hypo- and hyperkalaemia, respectively]. As a result, hypokalaemia,
but not hyperkalaemia, was strongly associated with death from
any cause.
In an exploratory landmark analysis, patients with two or more
episodes of hypokalaemia had a higher subsequent risk of the pri-
mary outcome [HR (95% CI) 1.32 (1.07–1.62); P = 0.009 and 1.20
















. (online supplementary Table S3). Averaging all potassium mea-
surements during the first 8 months of the trial showed that
hypokalaemia had a stronger association with subsequent primary
endpoints than hyperkalaemia [HR (95% CI) 1.35 (1.03–1.75);
P = 0.028 and 1.22 (0.95–1.57); P = 0.12, for hypo- and hyper-
kalaemia, respectively; online supplementary Table S3].
The associations reported in Table 2 remained similar when
an adjustment was made for time-updated use of diuretics,
reinforcing the stronger association of hypokalaemia (compared
with hyperkalaemia) with worse outcomes (online supplementary
Table S4).
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Association of time-updated serum potassium with
the study primary outcome. The primary outcome was a compos-
ite of total (first and recurrent) heart failure hospitalisations and
cardiovascular death. Both hypo- and hyperkalaemia were associ-
ated with the study primary outcome. Yellow bars, histogram of
time-updated potassium. CI, confidence interval.
Serum potassium by renal function
and treatment interaction
A significant time-updated serum potassium-by-kidney function
(eGFR <60 vs. ≥60 mL/min/1.73 m2) interaction was found for
the outcomes of cardiovascular death and all-cause death (inter-
action P<0.05 for both) as shown in the Table 3. Patients with
impaired renal function had higher risk of both cardiovascular
and non-cardiovascular death in the presence of hypokalaemia,
but not in the presence of hyperkalaemia, whereas patients with
normal renal function experienced no excess of risk related
to either type of potassium perturbation (Table 3). These find-
ings are expanded in Figure 2 where we can see that patients
with an eGFR <60 mL/min/1.73 m2 had a higher risk of mortal-
ity than patients with an eGFR ≥60 mL/min/1.73 m2 regardless
of the potassium level; however, the mortality risk is particu-
larly high (by more than twofold) among patients with impaired
renal function and potassium levels <4 mmol/L. On the other
hand, the risk of death is not influenced by potassium levels
among patients with an eGFR ≥60 mL/min/1.73 m2. Analyses with
further eGFR subgrouping are shown in online supplementary
Table S5.
The effect of sacubitril/valsartan, compared with valsartan, was
not modified by baseline potassium levels: treatment-by-potassium
P for interaction for the primary outcome =0.96; total
heart failure hospitalisations =0.96; cardiovascular death
=0.25; all-cause death =0.13; non-cardiovascular death =0.31
(Table 2).
Serum potassium levels over time
No significant differences in the level of serum potassium were
found between the sacubitril/valsartan and valsartan groups, irre-




















































































Table 3 Significant interactions of time-updated




HR (95% CI) P-value eGFR by K+
interaction
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CV death
K+ in eGFR ≥60
<4 0.65 (0.34–1.22) 0.18
4–5 Referent –
>5 0.81 (0.42–1.57) 0.54
K+ in eGFR <60 0.004
<4 1.98 (1.42–2.75) <0.001
4–5 Referent –
>5 1.28 (0.94–1.73) 0.11
All-cause death
K+ in eGFR ≥60
<4 0.94 (0.62–1.44) 0.77
4–5 Referent –
>5 1.10 (0.69–1.74) 0.69
K+ in eGFR <60 0.042
<4 1.88 (1.45–2.43) <0.001
4–5 Referent –
>5 1.06 (0.82–1.35) 0.67
CI, confidence interval; CV, cardiovascular; eGFR, estimated glomerular filtration
rate (mL/min/1.73 m2); HR, hazard ratio; K+ , serum potassium (mmol/L).
Discussion
This analysis showed that in patients with HFpEF, a serum potas-
sium <4 mmol/L or >5 mmol/L was associated with higher rates
of hospitalisation for heart failure than observed in patients with
a potassium between 4 and 5 mmol/L. The elevation in risk was
more marked for hypokalaemia than for hyperkalaemia. The risk
of death was also higher in patients with hypokalaemia, but not in
patients with hyperkalaemia. Furthermore, there was an interac-
tion between potassium and kidney function, whereby the elevated
risk of death related to hypokalaemia was only observed in patients
with impaired kidney function (eGFR <60 mL/min/1.73 m2). The
effect of sacubitril/valsartan was not modified by serum potassium
and the mean potassium levels throughout follow-up did not differ
significantly between the sacubitril/valsartan and valsartan groups.
The association between serum potassium and clinical outcomes
has been documented less often in HFpEF than in HFrEF,23 although
the few studies that have examined this question in HFpEF have
described a U-shaped relationship between potassium and mor-
tality, similar to that seen in HFrEF.1,2,24 However, the studies to
date have focussed on all-cause and cardiovascular death, and the
elevated risk of death has been attributed to the occurrence of
fatal ventricular arrhythmias, related to disturbances in potassium.
However, our finding that hypo- and hyperkalaemia were each asso-
ciated with heart failure hospitalisation questions this postulated
mechanism, as does the association between hypokalaemia and
non-cardiovascular death. There is no clear, direct, mechanism by
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Time-updated serum potassium-by-renal func-
tion interaction. eGFR, estimated glomerular filtration rate
(mL/min/1.73 m2). Patients with an eGFR <60 mL/min/1.73 m2
had a higher mortality risk than patients with eGFR
≥60 mL/min/1.73 m2, regardless of potassium level. How-
ever, the risk is particularly elevated (by more than twofold)
when both an eGFR <60 mL/min/1.73m2 and a potassium
<4.0 mmol/L were present; P for interaction <0.05 for both
outcomes. Yellow bars, histogram of time-updated potassium.
CI, confidence interval.
which hypo- or hyperkalaemia should be associated with either of
these outcomes, suggesting that potassium perturbations in most
cases are more likely markers rather than mediators of risk.
The stronger relationship between hypokalaemia and adverse
outcomes, compared with hyperkalaemia, may reflect the
specific exclusion of patients with an elevated potassium at
screening and during the run-in phases in PARAGON-HF,
and the protocol-mandated monitoring for and correction of
hyperkalaemia (there were no specific recommendations for
management of hypokalaemia in the protocol).
The interaction between hypokalaemia and renal impairment in
relation to fatal outcomes is of interest. An association between
eGFR and hyperkalaemia might have been expected more than an
association with hypokalaemia. We think the unexpected associ-
ation between low eGFR and hypokalaemia (rather than hyper-
kalaemia) may reflect the intensity of non-MRA diuretic use and the




















































































Figure 3 Potassium levels over time by treatment group and
mineralocorticoid receptor antagonist (MRA) treatment. No sig-
nificant between-group differences were present.
of the latter across the three potassium categories (hypokalaemia
22.0%, normokalaemia 26% and hyperkalaemia 32%).14,25 Given the
findings of the Treatment of Preserved Cardiac Function Heart
Failure With an Aldosterone Antagonist study (TOPCAT), sug-
gesting therapy with spironolactone may benefit at least some
patients with HFpEF,14 MRAs could be considered in this pop-
ulation as they also decrease hypokalaemia, which is strongly
associated with adverse outcomes. Furthermore, PARAGON-HF
patients treated with sacubitril/valsartan and MRAs had a less
pronounced annualised eGFR decline and did not experience
excess adverse events including severe hyperkalaemia (potassium
>6.0 mmol/L), which further support the concomitant use of MRAs
with sacubitril/valsartan.26
Hypokalaemia and kidney impairment have been associated with
higher use of diuretics, lower use of RAAS inhibitors (including
MRAs), and malnutrition,27 all of which may contribute to poor
outcomes. Furthermore, models adjusted for time-updated use
of diuretics reinforced the association between hypokalaemia (and
not hyperkalaemia) with worse outcomes, supporting the hypoth-
esis that the potassium alterations (hypokalaemia in this case)
are more of a marker of worse symptoms and HFpEF severity
that can arise as a consequence of diuretic therapy intensification,
rather than a direct cause of events. It should also be noted that,
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in time-updated models, it is the last potassium value registered
before the event that is considered, supporting the prompt cor-
rection of hypokalaemia (as soon as detected) regardless of the
cause or course.
Our findings differ somewhat from those in patients with HFrEF
in the Prospective Comparison of ARNI with an ACE-Inhibitor
to Determine Impact on Global Mortality and Morbidity in
Heart Failure trial (PARADIGM-HF).28 In that trial, both hyper-
and hypokalaemia were independently associated with heart fail-
ure hospitalisation, again suggesting that potassium abnormali-
ties are mainly markers of disease severity. However, both high
as well as low potassium were associated with death (including
non-cardiovascular death) in PARADIGM-HF and there was no
interaction with renal function. The explanation for these differ-
ences is uncertain, but may be due to difference in patient char-
acteristics in the two trials, with participants in PARAGON-HF
considerably older than in PARADIGM-HF (mean age 73 vs.
64 years) and with worse renal function (mean eGFR 63 vs.
68 mL/min/1.73 m2).
In PARAGON-HF, sacubitril/valsartan did not reduce the mean
serum potassium compared with valsartan, which was also different
than in PARADIGM-HF where, sacubitril/valsartan reduced mean
serum potassium concentration compared with enalapril. This
difference may again be due to the different study populations or in
the active comparator. However, in both trials sacubitril/valsartan
reduced the incidence of significant hyperkalaemia, i.e. a potassium
>6 mmol/L.19,29
Limitations
This was a post-hoc analysis of the PARAGON-HF trial. Patients
had to tolerate recommended doses of valsartan and sacubi-
tril/valsartan, which may reduce the generalisability of our findings.
Regular monitoring of potassium and protocol-guided mitigation
might have led to a prompt correction of potassium abnormali-
ties which may not occur in routine practice. Serum potassium
level >5.2 mmol/L at screening (or >5.4 mmol/L at randomisation)
was an exclusion criterion, which might have led to the selection
of patients less prone to develop hyperkalaemia and the proto-
col included recommendations to manage hyperkalaemia, both of
which may have reduced the impact of hyperkalaemia relative to
hypokalaemia in the trial. However, as potassium changes over
time, the time-updated analyses were more informative because
they accounted for the last potassium value available before the
event. Routine laboratory analyses, including potassium, were per-
formed at local laboratories and some cases of haemolysis might
have occurred. Diuretic doses are not standardised and are incon-
sistently reported as ‘free text’ in the dataset, which would lead to
unreliable data; therefore, we did not adjust for the dose of diuret-
ics in our models. We do not report data on non-fatal arrhythmias
because these were not systematically recorded in the dataset. The
use of potassium supplements or binders was not systematically
recorded in the trial. The proportion of patients with potassium
levels <3.5 mmol/L and >5.5 mmol/L was small; hence, these find-
ings cannot be generalised to patients with either very low or very




















































































Both hypo- and hyperkalaemia were associated with heart failure
hospitalisations but only hypokalaemia was associated with mortal-
ity, especially in the context of renal impairment. Hypokalaemia was
as strongly associated with death from non-cardiovascular causes
as with cardiovascular death. Collectively, these findings suggest
that potassium disturbances are a more of a marker of HFpEF
severity rather than a direct cause of death.
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Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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